Titan

[Titan @Fpltitan]

$TNXP almost 24% shorted, 12.1 days to cover
BIG earnings beat due Monday, shorts are pretty screwed here

Primed for short squeeze @TheRoaringKitty @wallstreetbets

[Titan @Fpltitan]

$TNXP is going to beat Q2 earnings next week, heavily shorted, they will be panicking to cover very soon! Tonmya sales are massive 🚀🚀🚀

[Titan @Fpltitan]

$TNXP climbing all week ahead of Q2 earnings on 10th August, expect a beat, huge shorts, primed for a short squeeze $TNXP

[Titan @Fpltitan]

$TNXP
Lyme drug phase 2 agreed with FDA ✅
Q2 earnings 10th Aug 💰
Japan partner & Europe partner being lined up 💰💰💰💰

[Titan @Fpltitan]

$TNXP is going to beat Q2 earnings next week, heavily shorted, they will be panicking to cover very soon! Tonmya sales are massive 🚀🚀🚀

[Titan @Fpltitan]

$TNXP
Lyme drug phase 2 agreed with FDA ✅
Q2 earnings 10th Aug 💰
Japan partner & Europe partner being lined up 💰💰💰💰

[Tonix Pharmaceuticals @TonixPharma]

The Tonix management team will be attending two upcoming investor conferences:

▪️ @CG_Driven 46th Annual Growth Conference

▪️ @MorganStanley 24th Annual Global Healthcare Conference

Learn more about our participation: https://t.co/z4FasEBzCW

#Biotech #Innovation #Investors

[Titan @Fpltitan]

$TNXP climbing all week ahead of Q2 earnings on 10th August, expect a beat, huge shorts, primed for a short squeeze $TNXP

[Titan @Fpltitan]

$TNXP about to have a big beat on Q2 earnings…short squeeze is primed as days to cover is over 7 and big amount of float shorted…

[Titan @Fpltitan]

$TNXP just got it’s Lyme trial approved at FDA. Major upside and it’s about to beat Q2 earnings again with its roll out of Tonmya

[Titan @Fpltitan]

@WalkerFran80950 It’s exactly the stock that can re-rate sharply, relatively small float, heavily shorted, growing institutional ownership, multiple catalysts, the perfect storm for a short squeeze $TNXP

[Titan @Fpltitan]

This is from Reddit… someone took the time to look at sales figures & it looks like a big beat, market expected $7.22 million net for Q2

[Titan @Fpltitan]

$TNXP about to have a big beat on Q2 earnings…short squeeze is primed as days to cover is over 7 and big amount of float shorted…

[Titan @Fpltitan]

@lee92579 @DailyLoud You Sir, are a fucking idiot

[Titan @Fpltitan]

$TNXP $1.3-1.4 million per week of Tonmya sales and growing…
It’s going to blast Q2 earnings estimates and the shorts know it! They are pushing price down to panic retail, sell at your peril, short squeeze or primed, 7.2 days to cover!!! $TNXP

[Titan @Fpltitan]

@SabahatAli91952 RFK is focused on Lyme and hates vaccines so TNXP product will appeal to him. Fast track very likely and the first Lyme drug ever made to the market, great potential $TNXP

[Titan @Fpltitan]

$TNXP just got it’s Lyme trial approved at FDA. Major upside and it’s about to beat Q2 earnings again with its roll out of Tonmya

[Titan @Fpltitan]

@DonnaAnnleffler Insurance coverage has expanded… sales are growing, over $1.4 million weekly easily now

[Titan @Fpltitan]

$TNXP $1.3-1.4 million per week of Tonmya sales and growing…
It’s going to blast Q2 earnings estimates and the shorts know it! They are pushing price down to panic retail, sell at your peril, short squeeze or primed, 7.2 days to cover!!! $TNXP

[Titan @Fpltitan]

$TNXP >$1.3 million per week on Tonmya sales & growing. It’s going to have a big beat for its Q2 earnings in august. Blockbuster painkiller Tonmya, stock hugely undervalued, but the sales growth speaks for itself & stock price will catch up soon $TNXP

[Titan @Fpltitan]

$TNXP sales growth is excellent, insurance coverage is expanding now, more insider buying during last 24 hours.
Massively undervalued in the market, expect a strong bounce, the sales can’t be ignored for long $TNXP Tonmya blockbuster drug in the making